Navigation Links
HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
Date:8/9/2013

FRAMINGHAM, Mass. and SYDNEY, Aug. 9, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Canaccord Genuity 2013 Annual Growth Conference at 3:00 p.m. EDT on Wednesday, August 14, 2013.  The conference is being held August 14-15 at the The InterContinental Boston.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 35 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Completes Acquisition Of World Heart Corporation
9. HeartWare Reports Second Quarter 2012 Results
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017  Orexigen Therapeutics, Inc. (Nasdaq: ... the fourth quarter and year ended December 31, 2016. ... transformational progress for Orexigen, beginning with the re-acquisition of ... early March, the team at Orexigen demonstrated remarkable focus, ... reshaped and strengthened our Company while rewarding us full ...
(Date:3/28/2017)... 2017 The global market for ... the top three companies, namely Shimadzu Corporation, Thermo Fisher ... 49% of the overall market in 2015, observes Transparency ... is intensely competitive and has few players, most of ... factors have restricted the entry of new players in ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 /PRNewswire/ ... Israel . This new business entity, Emosis Ltd, headquartered ... to research and development of novel assays complementing the mother company ... relevant, locally support commercialization and sales development of Emosis kits. ... This strategic move starts ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, ... ... a non-profit medical society dedicated to advancing the science and clinical practice ... from its RSSearch Patient Registry, a multi-institutional, observational registry established to standardize ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... March 28, 2017 , ... WHO: , Dr. Paul Thomas; Dr. ... , Medical doctors and PhD scientists will speak to the press on behalf of ... support of an independent vaccine safety commission. , WHERE: , Zenger Room, National ...
(Date:3/28/2017)... , ... March 28, 2017 , ... The Radiology ... FRBMA, has begun to serve as its new executive director. Mr. Still was selected ... Search Committee. , “Bob, as he is known to our members, has been ...
(Date:3/28/2017)... ... March 28, 2017 , ... Award-winning medical ... begin serving as new board chair for Orange County health care system CalOptima ... remainder of soon-to-be former chair Mark Refowitz’s term, which runs through June 30 ...
Breaking Medicine News(10 mins):